Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP13 | P45452 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MMP7 | P09237 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11511836 | 0.89 | ALDH1A1 (0.83) | ALDH1A1CYP2C9CA1CA2SMN1; SMN2 | |
| SCHEMBL3019231 | 0.84 | SIGMAR1 (0.70) | ALDH1A1SIGMAR1CYP2C9GAACYP19A1 | |
| SCHEMBL9577239 | 0.83 | SIGMAR1 (0.68) | ALDH1A1SIGMAR1GAACYP19A1MMP1 | |
| SCHEMBL8578107 | 0.81 | GAA (0.69) | ALDH1A1SIGMAR1GAACA1CA2 | |
| SCHEMBL126985 | 0.81 | ALDH1A1 (1.00) | ALDH1A1CYP2C9GAACYP19A1MMP1 | |
| SCHEMBL15836430 | 0.81 | ALDH1A1 (0.70) | ALDH1A1CYP2C9CA1CA2SMN1; SMN2 | |
| SCHEMBL3055959 | 0.81 | ALDH1A1 (0.70) | ALDH1A1CYP2C9CA1CA2SMN1; SMN2 | |
| SCHEMBL10476295 | 0.80 | ALDH1A1 (0.63) | ALDH1A1SIGMAR1CYP2C9LMNA | |
| SCHEMBL21820680 | 0.80 | ALDH1A1 (0.72) | ALDH1A1SIGMAR1GAACA1CA2 | |
| SCHEMBL12362795 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP2C9CA1CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2025-04-01 | — | — | US | disclosed |
| EP-3746437-B1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | HEPAREGENIX GMBH (DE) | 2024-04-11 | — | — | US | disclosed |
| CN-113999180-B | Quinazoline compound, intermediate, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-01-02 | — | — | US | disclosed |
| CN-111788195-B | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | 海帕瑞吉尼克斯股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-113999180-A | Quinazoline compound, intermediate thereof, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-106316965-B | Quinazoline compound, intermediate thereof, preparation method, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-7338962-B2 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| US-20070043073-A1 | Imidazopyridine-derivatives as inductible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| CN-1856491-A | Imidazopyridine derivatives as inducible NO synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1675854-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005030771-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116931-A1 | PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | MAPK4, MAP3K4, MAP4K1 | ALDH1A1 2857/4885SIGMAR1 4113/4885CYP2C9 2756/4885 |
| US-20070043073-A1 | Imidazopyridine-derivatives as inductible no-synthase inhibitors | NOS2, NOS1, NOS3 | ALDH1A1 351/4885SIGMAR1 819/4885CYP2C9 122/4885 |
| US-11858927-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | ALDH1A1 2857/4885SIGMAR1 4113/4885CYP2C9 2756/4885 |
| US-12264158-B2 | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAP3K4, MAP4K1 | ALDH1A1 2857/4885SIGMAR1 4113/4885CYP2C9 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.